Citigroup
IMVT icon

Citigroup’s Immunovant IMVT Stock Holding History

Citigroup’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59,200
Closed -$1.01M – 5771
2025
Q1 		$1.01M Hold
59,200
– – ﹤0.01% 3256
2024
Q4 		$1.47M Buy
59,200
+29,700
+101% +$842K ﹤0.01% 3062
2024
Q3 		$841K Buy
+29,500
New +$870K ﹤0.01% 3394
2023
Q2 		– Sell
-38,900
Closed -$603K – 5638
2023
Q1 		$603K Buy
+38,900
New +$675K ﹤0.01% 2982

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup's IMVT Position: Q2 2026 in Review

Citigroup increased its Immunovant (IMVT) stake by 358% in Q2 2026, buying an estimated $2.77M and bringing the position to 116,145 shares worth $4.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2245.

Citigroup first reported a position in IMVT in Q1 2020 and has held it in 26 quarters since. The position peaked at $8.07M in Q1 2024. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Citigroup held 116,145 shares of Immunovant worth $4.48M as of Q2 2026.
  • Citigroup bought 90,795 Immunovant shares in Q2 2026, an estimated $2.77M.
  • Immunovant made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2245 holding.
  • Citigroup first reported a position in Immunovant in Q1 2020 and has held it in 26 quarters since.
  • Citigroup's Immunovant position peaked at $8.07M in Q1 2024.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.